Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells 2,519 Shares of Stock

Key Points

• CTO Abhimanyu Verma sold 2,519 shares on April 6 at an average of $4.86 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from equity vesting (he also sold 1,030 shares on April 7), reducing his stake by 1.21% to 205,430 shares.
• SOPHiA GENETICS reported Q1 EPS of ($0.28), missing estimates of ($0.20) while delivering $21.71 million in revenue, and currently has mixed analyst coverage (two Buys, one Sell) with a consensus "Hold" and a $7.00 target.
• The stock traded around $4.89 with a market cap of about $334.6M and a 12-month range of $2.58–$5.70, and institutional investors hold roughly 31.6% of shares, including a new ~$6.7M stake by Alta Wealth Advisors.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CTO Abhimanyu Verma sold 2,519 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $4.86, for a total transaction of $12,242.34. Following the sale, the chief technology officer owned 205,430 shares in the company, valued at approximately $998,389.80. This trade represents a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, April 7th, Abhimanyu Verma sold 1,030 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $5,016.10.

SOPHiA GENETICS Stock Down 0.3%

SOPHiA GENETICS stock traded down $0.01 during mid-day trading on Wednesday, reaching $4.89. 64,929 shares of the company's stock were exchanged, compared to its average volume of 188,371. The company has a market cap of $334.64 million, a P/E ratio of -9.58 and a beta of 1.04. SOPHiA GENETICS SA has a twelve month low of $2.58 and a twelve month high of $5.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The company has a fifty day moving average of $4.78 and a 200-day moving average of $4.68.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The business had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Sell-side analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

SOPH has been the subject of a number of recent research reports. BTIG Research reiterated a "buy" rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Guggenheim lifted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $7.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Alta Wealth Advisors LLC purchased a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $6,708,000. Dimensional Fund Advisors LP lifted its position in shares of SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock worth $148,000 after buying an additional 6,205 shares during the last quarter. Polen Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $102,000. XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $55,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.